Establishment of fulminant liver function failure model of rhesus

Abstract

The invention provides preparation of an animal model for screening hepatocyte growth-promoting regenerative medicines in fulminant liver function failure curing process and evaluating therapeutic effect of a tissue engineering liver supporting system or hepatic cell and stem cell transplantation by using amanitin and endotoxin lipopoly-saccharide, wherein an application method adopts single intraperitoneal instillation with dosage of 0.1mg / kg, and the dosage of the endotoxin is 1mug / kg. The invention further provides a method for preparing fulminant liver function failure and a fulminant liver function failure animal model prepared by the method. The animal model can be used for evaluation of biotechnological new drugs that a rodent animal model cannot accomplish, and can be used for the evaluation of tissue engineering liver, biological artificial liver, the hepatic cell and stem cell transplantation treatment technologies.

Description

technical field [0001] The invention relates to a method for preparing a rhesus monkey fulminant liver failure model. Background technique [0002] Acute hepatic failure (fulminant hepatic failure, FHF) is common clinically and is mostly caused by viral infection, extensive liver tissue resection, acute drug or poison injury, etc. The prognosis of the patient is dire, and the mortality rate is very high. There is no better way to treat it than liver transplantation. Limited by the severe shortage of donor organs, cell transplantation (mature liver cell or stem cell transplantation), bioartificial liver, tissue engineered liver, etc. have become current research hotspots, but their effectiveness is mostly in small animals (basically rats). obtained on Promoting liver cell regeneration is also a current research hotspot, but satisfactory progress has not been made, and an ideal drug that can significantly promote liver cell regeneration in a short period of time has not yet...

AI Technical Summary

Problems solved by technology

These drug-induced FHF models all have various defects, such as acetaminophen, which has poor reproducibility, and the survival time of animals varies greatly under the same dose; it is accompanied by methemoglobinemia, refractory anemia and other organ damage

D-Galactosamine has poor reproducibility (mortality and time to death vary greatly); high cost (1-2g / kg), not suitable for application in large animals

Thioacetamide (TAA) can easily lead to severe hypotension, hypoglycemia, hypothermia, and renal failure, and can directly cause nerve damage, which is indistinguishable from hepatic encephalopathy; it is highly toxic to experimenters

Viruses can also induce FHF, but their replication is difficult and their biological safety is poor

[0006] Surgical resection of all or most of the liver, or complete defluidization, can also establish the HFH model, but due to the time-consuming operation, large trauma, and large hemodynamic interference; unless the liver is transplanted in situ, the animal cannot survive; the liver itself not damaged

There is no report on the establishment of FHF animal models with large primates

Images